Appeal No. 96-0009 Application 08/104,417 Appellants argue (brief, page 15) that their specification (page 4, lines 11-14; page 13, lines 6-29; page 15, line 2 - page 16, line 14) shows that the recited inhibitors are selective to the transport system and do not bind glutamate receptors, and that the claimed method is useful for studying the neurotransport system. Appellants further argue (brief, page 18) that the specification (page 3, lines 21-31; Figure 3 and Examples II-IV) shows the specificity and effectiveness of the recited compounds in preventing the uptake of L-glutamate away from nerve synapses as indicated by a synaptosomal uptake assay which is well- established in the art. The second declaration of Dr. Bridges (paragraphs 4 and 5) presents in vivo tests on laboratory rats and in vitro tests which show that L-trans-pyrrolidine-2,4-dicarboxylate inhibits the transport of L-glutamate from nerve synapses. Regarding enablement, appellants also point out that their claimed invention is directed toward the application of inhibitor compounds to a nerve synapse to inhibit the uptake of the neurotransmitter away from the synapse, and is not directed toward the treatment of any particular disease 5Page: Previous 1 2 3 4 5 6 7 8 9 NextLast modified: November 3, 2007